Difference between revisions of "Small cell carcinoma of the urinary bladder"

From Libre Pathology
Jump to navigation Jump to search
Line 45: Line 45:
Features:
Features:
*See ''[[small cell carcinoma]]''.
*See ''[[small cell carcinoma]]''.
*If mixed histology, ''small cell carcinoma'' component must be majority of tumour; otherwise classified as ''urothelial carcinoma with small cell carcinoma component''.
*If mixed histology, ''small cell carcinoma'' component must be majority of tumour; otherwise classified as ''urothelial carcinoma with small cell carcinoma component''.<ref>{{Ref WHOGU2016|117-8}}</ref>


Note:
Note:

Revision as of 21:20, 17 May 2022

Small cell carcinoma of the urinary bladder
Diagnosis in short

Small cell carcinoma of the urinary bladder. H&E stain.
LM DDx small cell carcinoma of the prostate gland, lymphoma (large cell), other small round blue cell tumours
Stains pankeratin +ve, chromogranin +ve, synaptophysin +ve, CD56 +ve
Site urinary bladder
Symptoms +/-hematuria
Prevalence very rare
Prognosis poor
Clin. DDx other bladder tumours esp. urothelial carcinoma

Small cell carcinoma of the urinary bladder, abbreviated SCCUB, is a rare malignant neoplasm of the urinary bladder.

General

  • Very rare[1] - less than 1% of bladder cancers in one series.[2]
  • Poor prognosis[1] - survival ~ 11 months.[2]

Clinical:

  • Hematuria - typical presentation.[2]

Epidemiology:

Microscopic

Features:

  • See small cell carcinoma.
  • If mixed histology, small cell carcinoma component must be majority of tumour; otherwise classified as urothelial carcinoma with small cell carcinoma component.[3]

Note:

DDx:

Images

  • SmCC bladder - intermed. mag.

  • SmCC bladder - high mag.

  • SmCC bladder - very high mag.

IHC

  • Pankeratin +ve,
  • Chromogranin +ve.
  • Synaptophysin +ve.
  • CD56 +ve.
  • TTF-1 +ve/-ve.

Sign out

Urinary Bladder Tumour, Transurethral Resection:
     - SMALL CELL CARCINOMA, invades muscularis propria, see comment. 
     -- Please see synoptic report.

Comment:
The tumour consists of cohesive, small blue cells with nuclear moulding and necrosis.  There is no definite urothelial differentiation, and no other differentiation to suggest a particular primary site. 

The tumour stains as follows:
POSITIVE: CK7 (dot-like moderate, diffuse), chromogranin A (moderate, diffuse), synaptophysin (strong, diffuse), TTF-1 (strong, diffuse).
NEGATIVE: CK20, CD45 (lymphocytes in background), CD20, PSA, p63 (marks benign urothelium).
PROLIFERATION (Ki-67): >90%.

Small cell carcinoma of the urinary bladder is the main consideration, based the anatomical site of the specimen. The findings above should be considered in the context of the imaging and clinical history.

See also

References

  1. ↑ 1.0 1.1 Koga, F.; Yokoyama, M.; Fukushima, H. (Nov 2013). "Small cell carcinoma of the urinary bladder: a contemporary review with a special focus on bladder-sparing treatments.". Expert Rev Anticancer Ther 13 (11): 1269-79. doi:10.1586/14737140.2013.851605. PMID 24168010.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 Hou, CP.; Lin, YH.; Chen, CL.; Chang, PL.; Tsui, KH. (2013). "Clinical outcome of primary small cell carcinoma of the urinary bladder.". Onco Targets Ther 6: 1179-85. doi:10.2147/OTT.S49879. PMID 24009428.
  3. ↑ The International Agency for Research on Cancer (Author), H. Moch (Editor), P.A. Humphrey (Editor), T.M. Ulbright (Editor), V.E. Reuter (Editor) (2016). WHO Classification of Tumours of the Urinary System and Male Genital Organs (4th ed.). Lyon: World Health Organization. pp. 117-8. ISBN 978-9283224372.
Retrieved from "https://librepathology.org/w/index.php?title=Small_cell_carcinoma_of_the_urinary_bladder&oldid=52054"